Your shopping cart is currently empty

RET-IN-4 is a highly effective and specific RET inhibitor that can be administered orally. It demonstrates remarkable potency, with IC50 values of 1.29 nM, 1.97 nM, and 0.99 nM for inhibiting RET variants including RET (WT), RET (V804M), and RET (M918T), respectively. Moreover, RET-IN-4 exhibits superior selectivity towards kinases JAK2 (IC50 of 4.4 nM) and FLT3 (IC50 of 30.8 nM). Additionally, RET-IN-4 possesses pronounced anticancer properties.

| Pack Size | Price | USA Warehouse | Global Warehouse | Quantity |
|---|---|---|---|---|
| 5 mg | $970 | Inquiry | Inquiry |
| Description | RET-IN-4 is a highly effective and specific RET inhibitor that can be administered orally. It demonstrates remarkable potency, with IC50 values of 1.29 nM, 1.97 nM, and 0.99 nM for inhibiting RET variants including RET (WT), RET (V804M), and RET (M918T), respectively. Moreover, RET-IN-4 exhibits superior selectivity towards kinases JAK2 (IC50 of 4.4 nM) and FLT3 (IC50 of 30.8 nM). Additionally, RET-IN-4 possesses pronounced anticancer properties. |
| Targets&IC50 | RET (WT):1.29 nM (IC50), RET (M918T):0.99 nM (IC50), RET (V804M):1.97 nM (IC50) |
| In vitro | RET-IN-4 (compound 9) effectively inhibits the proliferation of Ba/F3 cells transformed by the NSCLC-associated KIF5B-RET fusion, with an IC50 value of 19 nM. Compared to BLU-667[1], RET-IN-4 demonstrates fewer 'off-target' effects. |
| In vivo | RET-IN-4 (compound 9; p.o.; 10-20 mg/kg; p.o.; daily; for 10 days) effectively suppresses KIF5B-RET-Ba/F3 cell-induced tumor growth in a dose-dependent manner in immunodeficient nude/nude mice models bearing KIF5B-RET Ba/F3 cells[1]. |
| Molecular Weight | 546.611 |
| Formula | C27H31FN10O2 |
| Cas No. | 2436473-55-9 |
| Smiles | C[C@H](N1CCOC2(CCN(CC2)c2nc(C)cc(Nc3cc(C)[nH]n3)n2)C1=O)c1ccc(nc1)-n1cc(F)cn1 |
| Relative Density. | 1.47 g/cm3 (Predicted) |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice/Shipping at ambient temperature. |
Dissolve 2 mg of the compound in 100 μL DMSO
to obtain a stock solution at a concentration of 20 mg/mL . If the required concentration exceeds the compound's known solubility, please contact us for technical support before proceeding.
1) Add 100 μL of the DMSO
stock solution to 400 μL PEG300
and mix thoroughly until the solution becomes clear.
2) Add 50 μL Tween 80 and mix well until fully clarified.
3) Add 450 μL Saline,PBS or ddH2O
and mix thoroughly until a homogeneous solution is obtained.
| Size | Quantity | Unit Price | Amount | Operation |
|---|

Copyright © 2015-2026 TargetMol Chemicals Inc. All Rights Reserved.